欣旺達(300207.SZ):擬使用合計不超23億元閒置募集資金進行現金管理
格隆匯12月1日丨欣旺達(300207.SZ)公佈,公司於2021年11月30日召開第五屆董事會第十九次會議、第五屆監事會第十九次會議,審議通過了《關於公司及其全資子公司使用部分閒置募集資金進行現金管理的議案》,同意公司及其全資子公司浙江鋰威能源科技有限公司(“浙江鋰威”或“全資子公司”)、浙江欣旺達電子有限公司(“浙江欣旺達”)使用合計不超過人民幣23億元的閒置募集資金進行現金管理。
此次使用閒置募集資金進行現金管理不存在變相改變募集資金用途的行為,並保證不影響募集資金項目的正常進行。在上述額度範圍內,資金可以循環滾動使用,使用期限自公司董事會審議通過之日起十二個月內。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.